FDA Colludes with APA to Keep Dangerous ECT Device on the Market
Excerpted from CCHR’s submission to the FDA opposing its 2015 proposal to reclassify the ECT device as a Class II low risk device. CCHR’s submission was submitted in March 2016. It is clear that the Food and Drug Administration (FDA) and American Psychiatric Association (APA) members know that the ECT device manufacturers are not going … Read more